Sociedad Americana de Hirudoterapia

Conservative management of neonatal cerebral sinovenous thrombosis with coexisting thrombophilia.

Case report published in Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis (2018)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportDesarrollo de fármacosKhatri et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2018

Abstract

: Neonatal cerebral sinovenous thrombosis (CSVT) comprises approximately 50% of all pediatric-related CSVT. Although guidelines support anticoagulation in pediatric CSVT, the role of anticoagulation in neonatal CSVT remains controversial. This case report details the course of a neonate diagnosed with extensive CSVT and concurrent bilateral thalamic and intraventricular hemorrhage. Due to existing hemorrhage at the time of diagnosis, anticoagulation therapy was not administered. Despite coexisting protein C and antithrombin deficiency, CSVT resolved spontaneously, and neurodevelopmental follow-up after 13 years suggests a good prognosis. Although our case had a positive outcome, the association between the use of anticoagulation with concurrent hemorrhage and long-term outcome in neonatal CSVT has not been investigated in prospective studies to firmly guide optimum treatment. Current literature and guidelines for the treatment of neonatal CSVT are reviewed in this article. Until robust studies are available, expert opinion recommends anticoagulation in a stable neonate with CSVT.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article
Indexed MeSH termsAnticoagulantsCerebral HemorrhageConservative TreatmentHumansInfant, NewbornSinus Thrombosis, IntracranialThrombophiliaTreatment Outcome

Resumen

: Neonatal cerebral sinovenous thrombosis (CSVT) comprises approximately 50% of all pediatric-related CSVT. Although guidelines support anticoagulation in pediatric CSVT, the role of anticoagulation in neonatal CSVT remains controversial.

Por qué esto importa para la hirudoterapia

This case report details the spontaneous resolution of neonatal cerebral sinovenous thrombosis without the use of anticoagulation therapy, despite coexisting thrombophilia and hemorrhage. The study addresses the controversial use of systemic anticoagulants in neonates, which shares a broad thematic connection to the anticoagulant mechanisms utilized in hirudotherapy. It highlights the clinical complexities of managing blood clotting in vulnerable patient populations where standard pharmaceutical interventions carry significant risks. However, the article features absolutely no mention of leeches, hirudotherapy, or leech-derived substances, making it strictly a clinical vignette on conservative medical management.

Citación

Conservative management of neonatal cerebral sinovenous thrombosis with coexisting thrombophilia.

Khatri et al. · Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis, 2018

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.